EUCTR2015-003539-37-Outside-EU/EEA进行中（未招募）不适用
An international, multicenter, randomized, open-label, parallel efficacy, and safety trial of intravenous zoledronic acid compared to intravenous pamidronate in children with severe osteogenesis imperfect.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ovartis
- 入组人数
- 158
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or Female children between 3 months and 17 years old
- •OI type I, III or IV
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 158
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Deformity or abnormality which would prevent spine bone density from being done
- •Any surgical bone-lengthening procedure
- •Any kidney diseases or abnormalities
- •Low calcium or vitamin D levels in the blood
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
不适用
An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202EOsteogenesis ImperfectaEUCTR2004-001666-40-HUovartis Pharma AG130
进行中（未招募）
1 期
An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202EOsteogenesis ImperfectaEUCTR2004-001666-40-BEovartis Pharma AG130
进行中（未招募）
不适用
An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202EOsteogenesis ImperfectaEUCTR2004-001666-40-GBovartis Pharma AG130
进行中（未招募）
1 期
Suitability of nitisinone in alkaptonuria (AKU).EUCTR2012-005340-24-GBniversity of Liverpool (UniLiv)40
进行中（未招募）
不适用
A Randomized, international, multi-center, open-label study to document pharmacokinetics and optimal timing of initiation of dronedarone TreatmEnt following long-term aMIodarone in patients with paroxysmal or perSistent Atrial Fibrillation whatever the reason for the change of treatment - ARTEMIS AF Long-TermParoxysmal or persistent atrial fibrillationMedDRA version: 14.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2010-019247-19-DKsanofi aventis groupe105